Madrigal Pharmaceuticals Soars +214.3%
$MDGL 200.50 +136.70
Announces positive topline results from pivotal Phase 3 MAESTRO-NASH Clinical Resmetirom Trial ; trial achieved both #liver histological improvement endpoints that FDA proposed
Resmetirom would be the first approved treatment for NASH, or nonalcoholic steatohepatitis, a disease that affects about 5% of adults in the United States.
The data gives the $MDGL a timely boost after it raised “going concern” doubts in November citing lack of adequate cash. This move would have also been impacted by short covering, squeezing based on that